Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

BACKGROUND: Uveal melanoma accounts for 85% of the ocular melanomas and has an increased risk of hematogenous spread, most commonly to the liver. After curative intent therapy like surgery and radiation, fifty percent of patients present with distant metastasis. Metastatic uveal melanoma (MUM) does...

Descripción completa

Detalles Bibliográficos
Autores principales: Afzal, Muhammad Zubair, Mabaera, Rodwell, Shirai, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809910/
https://www.ncbi.nlm.nih.gov/pubmed/29433557
http://dx.doi.org/10.1186/s40425-018-0322-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5809910/
https://www.ncbi.nlm.nih.gov/pubmed/29433557
http://dx.doi.org/10.1186/s40425-018-0322-1

Ejemplares similares